Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Long-term trajectories of hepatic and metabolic biomarkers after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral therapy-experienced people with HIV with and without hepatic coinfection: Data from the ICONA cohort.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2025
Same author

Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians' and nurses' points of view.

The Journal of antimicrobial chemotherapy·2024
Same author

Clinical characteristics of women with HIV in the RESPOND cohort: A descriptive analysis and comparison to men.

HIV medicine·2024
Same author

SARS-CoV-2 testing, positivity, and factors associated with COVID-19 among people with HIV across Europe in the multinational EuroSIDA cohort.

HIV medicine·2024
Same author

Monkeypox epidemic in prisons: How to prevent it?

The Lancet regional health. Europe·2022
Same author

Awareness and perception of accuracy of the Undetectable=Untransmittable message (U=U) in Italy: results from a survey among PLWHA, infectious-diseases physicians and people having unprotected sex.

AIDS care·2022

相关实验视频

Updated: Jul 14, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

在HIV-1感染中开始高活性抗逆转录病毒疗法后,停止Pneumocystis carinii肺炎预防. 欧洲SIDA研究小组

G J Weverling1, A Mocroft, B Ledergerber

  • 1Department of Infectious Diseases, Tropical Medicine and AIDS and the National AIDS Therapy Evaluation Centre, University of Amsterdam, The Netherlands.

Lancet (London, England)
|April 28, 1999
PubMed
概括

接受高活性抗逆转录病毒疗法 (HAART) 的患者,一旦CD4计数超过200细胞/microL,可以安全地停止初级肺囊炎肺炎 (PCP) 预防. 需要进一步的研究来证实中断二次PCP预防的安全性.

更多相关视频

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

相关实验视频

Last Updated: Jul 14, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

科学领域:

  • 传染性疾病 传染性疾病
  • 免疫学 免疫学 免疫学
  • 公共卫生 公共卫生

背景情况:

  • 高活性抗逆转录病毒疗法 (HAART) 显著改善了HIV-1感染个体的治疗结果.
  • 在接受HAART的患者中,预防Pneumocystis carinii肺炎 (PCP) 的作用需要重新评估.
  • 评估停止PCP预防的安全性对于优化患者护理至关重要.

研究的目的:

  • 为了确定是否可以安全地停止Pneumocystis carinii肺炎 (PCP) 预防在开始高活性抗逆转录病毒疗法 (HAART) 的患者.
  • 在HAART的背景下,分析停止初级和二级预防后PCP的发生率.
  • 评估CD4淋巴细胞计数,HIV-1RNA负载和PCP风险在预防后停药之间的关系.

主要方法:

  • 一项前性观察队列研究 (EuroSIDA) 涉及52个欧洲和以色列中心的7333名HIV-1感染患者.
  • 用人年分析来评估PCP预防停止率和HAART引入后PCP发生率.
  • 数据收集包括CD4淋巴细胞计数,血HIV-1RNA负载,以及在预防药物停止时记录的最低CD4淋巴细胞计数.

主要成果:

  • 在1998年3月之后,PCP预防药物停用率显著增加,达到每100人/年21.9人.
  • 378名患者停止了预防 (319名初级,59名二级) 在开始HAART后的10个月中位数.
  • 在停止治疗后的247人年随访期间,没有观察到PCP病例,在停止初级预防时,CD4细胞计数中位数超过200细胞/微升.

结论:

  • 由于PCP的风险足够低,在接受HAART的患者中,CD4淋巴细胞计数超过200细胞/μL的患者需要停止初级PCP预防.
  • 需要更长的随访时间来确定停止二次PCP预防的安全性.
  • 这些发现支持在HAART下的HIV-1管理中降低预防方案的升级.